Avanir Pharmaceuticals receives Complete Response Lette from FDA on AVP-825 NDA
Avanir Pharmaceuticals announced the FDA has issued a Complete Response letter to its New Drug Application for AVP-825. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath Powered delivery technology. November 26, 2014